10 results on '"Punthakee, Zubin"'
Search Results
2. Targeting skeletal muscle health with exercise in people with type 1 diabetes: A protocol for HOMET1D, a prospective observational trial with matched controls
- Author
-
Rebalka, Irena A., primary, Noguchi, Kenneth S., additional, Bulyovsky, Kayla R., additional, Badour, Matthew I., additional, Juracic, Emma S., additional, Barrett, Khandra, additional, Brahmbhatt, Aditya, additional, Al-Khazraji, Baraa, additional, Punthakee, Zubin, additional, Perry, Christopher G. R., additional, Kumbhare, Dinesh A., additional, MacDonald, Maureen J., additional, and Hawke, Thomas J., additional
- Published
- 2024
- Full Text
- View/download PDF
3. Evaluating remission of type 2 diabetes using a metabolic intervention including fixed‐ratio insulin degludec and liraglutide: A randomized controlled trial.
- Author
-
Punthakee, Zubin, Hall, Stephanie, McInnes, Natalia, Sherifali, Diana, Tsiplova, Kate, Kirabo, Faith R., Ransom, Thomas P. P., Harris, Stewart B., Lochnan, Heather A., Sigal, Ronald J., Ghosh, Mahua, Spaic, Tamara, and Gerstein, Hertzel C.
- Subjects
- *
TYPE 2 diabetes , *EXERCISE therapy , *EXECUTIVE coaching , *DISEASE remission , *BODY mass index , *INSULIN - Abstract
Aim Methods Results Conclusions To evaluate the effect on type 2 diabetes remission of short‐term intensive metabolic intervention consisting of frequent dietary, exercise and diabetes management coaching, metformin and fixed‐ratio insulin degludec/liraglutide.In a multicentre open‐label randomized controlled trial, insulin‐naïve participants within 5 years of diabetes diagnosis were assigned to a 16‐week remission intervention regimen or standard care, and followed for relapse of diabetes and sustained remission for an additional year after stopping glucose‐lowering drugs.A total of 159 participants aged 57 ± 10 years, with diabetes duration 2.6 ± 1.5 years, body mass index 33.5 ± 6.5 kg/m2, and glycated haemoglobin (HbA1c) level 53 ± 7 mmol/mol were randomized and analysed (79 intervention, 80 control). At the end of the 16‐week intervention period, compared to controls, intervention participants achieved lower HbA1c levels (40 ± 4 vs. 51 ± 7 mmol/mol; p < 0.0001), and lost more weight (3.3 ± 4.4% vs. 1.9 ± 3.0%; p = 0.02). There was a lower hazard of diabetes relapse overall in the intervention group compared to controls (hazard ratio 0.63, 95% confidence interval [CI] 0.45, 0.88; p = 0.007), although this was not sustained over time. Remission rates in the intervention group were not significantly higher than in the control group at 12 weeks (17.7% vs. 12.5%, relative risk [RR] 1.42, 95% CI 0.67, 3.00; p = 0.36) or at 52 weeks (6.3% vs. 3.8%, RR 1.69, 95% CI 0.42, 6.82) following the intervention period.An intensive remission‐induction intervention including fixed‐ratio insulin degludec/liraglutide reduced the risk of type 2 diabetes relapse within 1 year without sustained remission. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. An assessment of adaptation and fidelity in the implementation of an audit and feedback-based intervention to improve transition to adult type 1 diabetes care in Ontario, Canada
- Author
-
Ahmad, Syed Zain, primary, Ivers, Noah, additional, Zenlea, Ian, additional, Parsons, Janet A., additional, Shah, Baiju R., additional, Mukerji, Geetha, additional, Punthakee, Zubin, additional, and Shulman, Rayzel, additional
- Published
- 2024
- Full Text
- View/download PDF
5. The TRUST Study—TRansition US Together: Evaluating the Impact of a Parent- and Adolescent-Centered Transition Toolkit on Transition Readiness in Patients with Juvenile Idiopathic Arthritis and Childhood-Onset Systemic Lupus Erythematosus †.
- Author
-
Heera, Simran, Beattie, Karen, Punthakee, Zubin, DiRezze, Briano, Herrington, Julie, Cellucci, Tania, Heale, Liane, Matsos, Mark, Gorter, Jan Willem, and Batthish, Michelle
- Subjects
JUVENILE idiopathic arthritis ,SELF-management (Psychology) ,RESEARCH funding ,ACADEMIC medical centers ,BEHAVIOR modification ,DATA analysis ,QUALITATIVE research ,PARENT-child relationships ,QUESTIONNAIRES ,CONTENT analysis ,SYSTEMIC lupus erythematosus ,INFORMATION resources ,DESCRIPTIVE statistics ,TRANSITIONAL care ,LONGITUDINAL method ,SURVEYS ,COMMUNICATION ,TRANSITIONAL programs (Education) ,PSYCHOMETRICS ,MEDICATION therapy management ,HEALTH behavior ,STATISTICS ,SELF advocacy ,CONFIDENCE intervals ,DATA analysis software ,TRANSITION to adulthood - Abstract
Objective: Adolescents with chronic rheumatic disease must increasingly take on more responsibility for disease management from parents as they transition from pediatric to adult care. Yet, there are limited resources to inform and support parents about transition. Here, we evaluate the impact of a Transition Toolkit, geared towards parents and adolescents, on transition readiness, and explore the potential impact of parent–adolescent communication. Methods: A prospective cohort study of youths aged 14–18 years old and their parents was performed. Participant demographics, disease characteristics, transition readiness scores (Transition-Q, max 100), and parent–adolescent communication scores (PACS, max 100) were collected at enrollment (when the Transition Toolkit was shared with adolescents and their parents. Generalized estimating equation (GEE) analyses determined the influence of the Toolkit on transition readiness and explored the role of parent–adolescent communication quality. Subgroup analyses were conducted by sex. Results: A total of 21 patients were included; 19 completed one post-intervention Transition-Q and 16 completed two. Transition-Q scores increased over time and the rate of increase doubled after the Toolkit was shared (β = 7.8, p < 0.05, and β = 15.5, p < 0.05, respectively). Conclusion: Transition readiness improved at each follow-up, the greatest increase was seen after the Toolkit was shared. Parent–adolescent communication quality did not appear to impact changes in transition readiness. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Characteristics of Abdominal Visceral Adipose Tissue, Metabolic Health and the Gut Microbiome in Adults.
- Author
-
U-Din, Mueez, Ahmed, Basma A., Syed, Saad A., Ong, Frank J., Oreskovich, Stephan M., Gunn, Elizabeth, Surette, Michael G., Punthakee, Zubin, Steinberg, Gregory R., and Morrison, Katherine M.
- Subjects
ABDOMINAL adipose tissue ,GUT microbiome - Abstract
Context: Compared with the relatively benign effects of increased subcutaneous adipose tissue (SAT), increased visceral adipose tissue (VAT) volume is a causal risk factor for hypertension, hyperlipidemia, type 2 diabetes, and cardiovascular disease. In rodents, increased VAT volume and triglyceride density and ectopic lipid accumulation in kidneys and liver have been induced by alterations in the gut microbiome. However, few studies have characterized these relationships in humans. Objective: To evaluate the tissue triglyceride content of VAT and SAT, liver, kidneys, and pancreas in male and female adults and assess associations with markers of glucose tolerance, serum insulin, and lipids and characteristics of the gut microbiome. Methods: Cross-sectional observational study of healthy human adults (n = 60) at a clinical research center. Body mass index (BMI), body composition, and oral glucose tolerance were assessed. Microbiome analysis was conducted on stool samples using 16S rRNA v3 amplicon sequencing. The triglyceride content of VAT, SAT, liver, kidney and pancreas were determined by assessing proton density fat fraction (PDFF) with magnetic resonance imaging (MRI). Results: Higher VAT PDFF and the ratio of VAT to SAT PDFF were related to higher BMI, HbA1c, HOMA-IR, non-high–density lipoprotein cholesterol, plasma triglycerides, low-density lipoprotein (LDL) cholesterol, and lower high-density lipoprotein (HDL) cholesterol. A higher VAT PDFF and VAT to SAT PDFF ratio were associated with lower alpha diversity and altered beta diversity of the gut microbiome. Differences in VAT were associated with higher relative abundance of the phylum Firmicutes, lower relative abundance of the phylum Bacteroidetes, and enrichment of the bacterial genera Dorea, Streptococcus, and Solobacterium. Conclusion: VAT PDFF measured with MRI is related to impaired glucose homeostasis, dyslipidemia, and differences in the gut microbiome, independently of the total body fat percentage [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. The Diabetes Health Coaching Randomized Controlled Trial: Rationale, Design and Baseline Characteristics of Adults Living With Type 2 Diabetes
- Author
-
Sherifali, Diana, Brozic, Anka, Agema, Pieter, Gerstein, Hertzel C., Punthakee, Zubin, McInnes, Natalia, O'Reilly, Daria, Ibrahim, Sarah, and Usman Ali, R. Muhammad
- Abstract
The Diabetes Health Coaching Trial was a single-blind, randomized controlled trial designed to evaluate the effect of a 1-year telephone-based diabetes health-coaching intervention for community-dwelling adults living with type 2 diabetes mellitus. It concerned glycated hemoglobin levels, self-care behaviours and cost-effectiveness. The purpose of this article is to describe the rationale, design and participants' characteristics.
- Published
- 2024
- Full Text
- View/download PDF
8. Adherence to Guidelines for Inpatient Pharmacologic Management of Type 2 Diabetes and Glycemic Outcomes
- Author
-
Alkhiari, Resheed, Alzayer, Hussain, Aljazeeri, Jafar, Vanniyasingam, Thuva, and Punthakee, Zubin
- Abstract
Diabetes is often poorly managed in hospitals. This study assessed the level of adherence to current Canadian practice guidelines for inpatient pharmacologic management of type 2 diabetes and whether it affected the frequency of hyperglycemia or hypoglycemia.
- Published
- 2024
- Full Text
- View/download PDF
9. Treatment of Subclinical Hyperthyroidism and Incident Atrial Fibrillation.
- Author
-
Jay, Mohammad, Huan, Peter, Cliffe, Nikki, Rakoff, Jonah, Morris, Emily, Kavsak, Peter, Luthra, Meera, and Punthakee, Zubin
- Abstract
ABSTRACT Context Objective Design Patients Main Outcomes Results Conclusion Treating overt hyperthyroidism prevents atrial fibrillation (AF). Though subclinical hyperthyroidism (SH) has been associated with AF, it is unknown whether treating SH prevents AF.We aimed to identify the association between treating SH and incident AF.In a pharmacoepidemiologic retrospective cohort study, patients diagnosed with SH between 2000 and 2021 were followed.Outpatients ≥ 18 years with biochemical SH and without prior AF, hypothyroidism, thyroid cancer, pituitary disease, or pregnancy were included.The primary outcome was incident AF. Secondary outcomes were ECG and echocardiographic features associated with AF.Of 2169 patients screened, 360 (131 treated and 229 untreated) were followed up for a mean of 4.27 years. In the treated and untreated groups, AF occurred in 4 (3.1%) and 15 (6.6%) patients (
p = 0.15), and AF incidence was 0.8% and 1.4%/year (p = 0.31), respectively. The hazard ratio (HR) for treatment as a time‐dependent variable was 0.60 (95% CI 0.19–1.92;p = 0.39). As some cases of AF were documented nearly simultaneously with SH treatment, a sensitivity analysis was performed reassigning two patients diagnosed with AF < 30 days after starting SH treatment to the untreated group. Here, in the treated and untreated groups, AF occurred in 1.6% and 7.4% (p = 0.02), and AF incidence was 0.4% and 1.8%/year (p = 0.02), respectively. The HR was 0.25 (0.06–1.13;p = 0.07). There were no differences in ECG or echocardiographic features.There was an overall trend towards lower incidence and prevalence of AF following treatment of SH, supporting the need for larger scale studies. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
10. COVID-19 vaccine effectiveness among South Asians in Canada.
- Author
-
Chanchlani R, Shah BR, Bangdiwala SI, de Souza RJ, Luo J, Bolotin S, Bowdish DME, Desai D, Everett K, Lear SA, Loeb M, Punthakee Z, Sherifali D, Wahi G, and Anand SS
- Abstract
We evaluated the effectiveness of COVID-19 vaccines among South Asians living in Ontario, Canada compared to non-South Asians and compared the odds of symptomatic COVID-19 infection and related hospitalizations and deaths among non-vaccinated South Asians and non-South Asians. This was a test negative design study conducted in Ontario, Canada between December 14, 2020 and November 15, 2021. All eligible individuals >18 years with symptoms of COVID-19 were subdivided by ethnicity (South Asian vs other) and vaccination status (vaccinated versus not). The primary outcome was vaccine effectiveness as defined by COVID-19 infections, hospitalizations, and deaths, and secondary outcome was the odds of COVID-19 infections, hospitalizations, and death comparing non-vaccinated South Asians to non-vaccinated non-South Asians. 883,155 individuals were included. Among South Asians, two doses of COVID-19 vaccine prevented 93.8% (95% CI 93.2, 94.4) of COVID-19 infections and 97.5% (95% CI 95.2, 98.6) of hospitalizations and deaths. Among non-South Asians, vaccines prevented 86.6% (CI 86.3, 86.9) of COVID-19 infections and 93.1% (CI 92.2, 93.8) of hospitalizations and deaths. Non-vaccinated South Asians had higher odds of symptomatic SARS-CoV-2 infection compared to non-vaccinated non-South Asians (OR 2.35, 95% CI 2.3, 2.4), regardless of their immigration status. COVID-19 vaccines are effective in preventing infections, hospitalizations and deaths among South Asians living in Canada. The observation that non-vaccinated South Asians have higher odds of symptomatic COVID-19 infection warrants further investigation., Competing Interests: The authors have read the journal’s policy and have the following competing interests: SSA holds a Tier 1 Canada Research Chair in Ethnic Diversity and Cardiovascular Disease (#CRC-2017-00024), and the Michael G DeGroote Heart and Stroke Foundation of Canada Chair in Population Health Research outside of the submitted work. ML sits on vaccine advisory boards for Seqirus, Pfizer, Sanofi, Medicago, GSK, Merck, Novovax, and Janssen; is on the Data Safety Monitoring Board for CanSino Biologics, has received funding from Seqirus for a vaccine trial, is receiving in-kind supply of smallpox vaccines from Bavarian Nordic, and has provided expert testimony about vaccines outside of the submitted work. DMEB holds a Tier 2 Canada Research Chair in Aging and Immunity, sits on vaccine advisory boards for Pfizer and AstraZeneca, has received consulting fees/honoraria for Pfizer and AstraZeneca, and has provided expert testimony about vaccines outside of the submitted work. SB is the Director of the Centre for Vaccine Preventable Diseases (CVPD) at the University of Toronto outside of the submitted work. The CVPD receives operational support from a mix of funding sources, including through donations from pharmaceutical companies. A robust set of governance practices are in place to safeguard the academic freedom of the CVPD. BRS is funded by the University of Toronto as the Novo Nordisk Research Chair in Equitable Care of Diabetes and Related Conditions outside of the submitted work. DS holds the Heather M. Arthur Population Health Research Institute/Hamilton Health Sciences Chair in Inter-Professional Health Research and has received an honorarium from Diabetes Update 2023 for being an invited speaker and is a co-methods lead on the Diabetes Canada Clinical Practice Guidelines Steering Committee outside of the submitted work. GW has received grants from the Canadian Institutes of Health Research and the Hamilton Health Sciences Foundation outside of the submitted work. RJdS has received grants from the Canadian Institutes of Health Research, Canadian Foundation for Dietetic Research, Population Health Research Institute, and Hamilton Health Sciences Corporation; he has received consulting fees and travel honoraria from the World Health Organization’s Nutrition Guidelines Advisory Group; he is an Independent Director for the Helderleigh Foundation (Canada) and Co-Chair of a method working group for the ADA/EASD Precision Medicine in Diabetes group outside of the submitted work. SIB has received grants from the Canadian Institutes of Health Research and from the International Development Research Centre; he also served as a member of the US National Institute of Allergy and Infectious Diseases Data and Safety Monitoring Board for COVID-19 Preventive monoclonal antibodies trials outside of the submitted work. All other authors declare that they have no competing interests. This does not alter our adherence to PLOS policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare., (Copyright: © 2024 Chanchlani et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.